Alzheimer's Disease Assessment and Management

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is a core factor contributing to neuronal injury in Alzheimer’s disease?

Cholinergic deficiency (correct)

Deficiency of GABA

Increased serotonin activity

Elevated dopamine levels

Which assessment tool was used to evaluate Mrs. Fatima's cognitive function?

Beck Depression Inventory

Montreal Cognitive Assessment (MoCA)

Glasgow Coma Scale

Mini-Mental State Examination (MMSE) (correct)

Which of the following is NOT typically a symptom associated with Alzheimer’s disease?

Bowel incontinence (correct)

Difficulty in word finding

Memory loss

Disorientation

What is an important aspect to consider when formulating treatment recommendations for patients with Alzheimer's disease?

Evaluating the safety and effectiveness through the stages of AD Signup and view all the answers

Which of the following modes of action is typically utilized by medications treating Alzheimer's disease?

Enhancement of cholinergic function Signup and view all the answers

What primary goal should be emphasized in the management of Fatima's condition?

Preserve patient function for as long as possible Signup and view all the answers

Which of the following is indicative of Fatima's history related to her psychiatric assessment?

She acknowledges her memory problems and feels depressed Signup and view all the answers

What additional therapy options should be considered for Fatima as her cognitive decline progresses?

Utilization of specific medications targeting cognitive decline Signup and view all the answers

What social factor may impact the management and therapy of Fatima's condition?

She resides alone, with limited social interaction Signup and view all the answers

Which comorbidity could complicate Fatima's treatment for cognitive decline?

Diabetes controlled with diet and metformin Signup and view all the answers

Which intervention should be prioritized for managing agitation in patients?

Use of environmental modifications Signup and view all the answers

What dietary approach is suggested to potentially reduce the risk of cognitive decline?

Mediterranean Diet Signup and view all the answers

What is the recommended initial pharmacologic treatment for mild to moderate cognitive symptoms?

AChIs with no preference for agents Signup and view all the answers

Which of the following factors is NOT identified as a primary prevention measure for cognitive decline?

Increased midlife obesity Signup and view all the answers

What effect might appropriate treatment have on a patient's decline in cognitive abilities?

Slowed decline in abilities Signup and view all the answers

What is the recommended initial approach for newly diagnosed Alzheimer's Disease (AD) patients regarding cholinesterase inhibitors?

Start a trial of a cholinesterase inhibitor for symptomatic treatment. Signup and view all the answers

Which of the following is NOT a cholinesterase inhibitor mentioned for treating mild to moderate AD?

Bupropion Signup and view all the answers

What should be done if a patient on cholinesterase inhibitors shows no benefit after six months?

Taper down the medication by 50% and evaluate. Signup and view all the answers

What is the expected benefit of cholinesterase inhibitors in terms of patient improvement?

Small improvements in cognition and neuropsychiatric symptoms over time. Signup and view all the answers

What is a recommended action if a patient tolerates therapy with cholinesterase inhibitors even without clear efficacy?

Re-evaluate treatment duration as no consensus exists. Signup and view all the answers

Study Notes

Alzheimer's Disease Module II

Learning Objectives: Students will learn to optimize medicine use and care for patients with Alzheimer's Disease (AD). By the end of the module, students will be able to demonstrate knowledge of AD epidemiology, etiology, and pathophysiology. They will understand the roles of amyloid beta, cholinergic deficiency and glutamate excess in neuronal injury. Students will also be able to recognize AD signs, symptoms, risk factors, and criteria for diagnosis and severity assessment; explain different modes of action for medications used in treating AD. Also describe key pharmacokinetic, pharmacodynamic properties, side effects, and potential drug interactions. Furthermore, students will formulate patient-specific goals, treatment efficacy, and monitoring plans for people with AD, as well as pharmacological and non-pharmacological strategies for behavioral psychological symptoms.

Case Study: Mrs. Fatima

Demographics: 73-year-old female
Chief Complaint (CC): Increasing memory problems (forgetfulness with paying bills, stove on, etc.) over 2 years
History of Present Illness (HPI): Memory problems worsening over the past two months; confusion, disorientation, agitation, refusing to pay bills when stating already paid. She also reports her mother had memory issues.
Past Psychiatric History (PPH): Problems sleeping, depression related to cognitive decline, no changes in appetite or suicidal ideation
Past Medical History (PMH): Diabetes (diet and metformin for controlling), history of gastric ulcers (antacid for heartburn), constipation (stool softener).
Social History (SH): Widow for 3 years, one daughter in Jordan and the other a housewife with 3 children. Lives close to daughter; housekeeper except weekends. Never smoked or consumed alcohol.

Reflect on the Disease

Task: Write about a patient's life with AD, and their therapy options; individual insights and aspirations on the topic
Duration: 2 minutes of writing

AD Mind Map

Mild to moderate AD: Use Cholinesterase Inhibitors (AChIs) based on ADRs and dose forms. Consider aducanumab.
Moderate to severe AD: Use memantine monotherapy. Add memantine to existing AChIs. Or memantine + Donepezil.
Goal of treatment: Maintain function/Reduce symptoms, manage psychiatric & behavioral symptoms
Approach: Medication, supportive care, lifestyle, etc.
Specific strategies: Use of specialized therapies for cognitive decline, behavioral/emotional problems and other medical complications of AD

Goals of Therapy

Primary Goal: Treat symptoms associated with cognitive decline and preserve patient function
Secondary Goals: Manage psychiatric and behavioral sequelae, modify and reduce risk factors.

AD - Management Principles

Early Stages: Discuss with patient and family, define patient-specific treatment goals. Refer to early-stage groups or adult day services for activities.
Intermediate Stages: Use AD-specific medications to treat cognitive decline, treat behavioral symptoms and mood disorders using non-pharma approaches.
Late Stages: If non-pharmacological is unsuccessful, use medications for specific behaviors. Provide appropriate treatment for medical conditions and offer end-of-life care when needed.

Nonpharmacologic Therapy

Identify causative factors: Cognitive and non-cognitive symptoms and adapt the caregiving environment to address them.
Sleep Disturbances: Behaviours and environmental interventions
Urinary Incontinence, Agitation and Aggression: Manage use of behavioral and environmental interventions
Lifestyle changes: On initial diagnosis: educate patients and caregivers on the illness course, available treatments, legal decisions, quality-of-life issues.
Primary prevention: Smoking cessation, physical activity, reduction of midlife obesity, hypertension, diabetes, adherence to the Mediterranean Diet or DASH diet may reduce the risk.

Pharmacologic Therapy of Cognitive Symptoms

Mild to moderate: Select AChIs based on ADRs and forms. Consider aducanumab.
Moderate to severe: Use memantine monotherapy, add memantine to existing AChIs, or memantine + Donepezil.

Cholinesterase Inhibitors

Drugs: Donepezil, rivastigmine, and galantamine
Use: First-line therapy for mild-moderate AD, also indicated for severe AD
Duration: Assess efficacy, stop if ineffective or switch to Memantine. Don't switch Cholinesterase inhibitors.
Monitoring: 6 months on target dose. Re-evaluate and taper down by 50% if no benefit.

Cholinesterase Inhibitors: Dose and Administration

(Table of drugs, forms, initial, maintenance,dosage and comments)

Options for Patients on Enteral Feeding

Diagram: (Illustation of nasogastric tube, nasal cavity, esophagus, and stomach) Shows how the feeding is conducted.

Cholinesterase Inhibitors: Benefit and Monitoring

Benefit: Modest improvements in cognitive, neuropsychiatric symptoms, and daily living activities
NNT: Over minimum of 12 weeks
Side effects: (Nausea, vomiting, diarrhea, insomnia, vivid/abnormal dreams, etc.)
Monitoring: Heart rate monthly during titration. Blood pressure, and weight checks every six months.

Monitoring Treatment with AChIs

Baseline tests: Urea, electrolytes, liver function, blood pressure
Monitoring during treatment: Heart rate, blood pressure, weight, and side effects
Other side effects: Muscle cramps, bradycardia, increased gastrointestinal acid, appetite decrease, and weight loss

N-methyl-D-aspartate (NMDA) receptor antagonists

Drug: Memantine
Use: Indicated for moderate to severe AD as monotherapy
Combination: May be combined with donepezil (Namzaric) to mitigate GI effects of cholinesterase inhibitors.
Use in Mild AD: Not indicated for mild AD (no significant benefit)
Other indications: Vascular or mixed dementia; older adults with Down Syndrome may not achieve benefit

Memantine Dosing

Initial: 5 mg once daily
Dose increase: 5 mg weekly increase up to maximum tolerated dose of 20 mg per day.
Extended release: Available form

Monitoring Treatment - Cholinesterase Inhibitors and Memantine

Patient reassessment: 2-4 months after reaching maintenance dose and every 6 months thereafter. Monitor cognition (MMSE score), activities of daily living (ADLs). Monitor overall clinical response, including side effects.

When to Stop Cholinesterase Inhibitors and Memantine

( Flowchart showing decision tree for stopping medication based on patient and clinical factors)

Disease-modifying therapies (DMTs)

Aimed at: Modifying the course of AD rather than managing symptoms
Drugs: Aducanumab and Lecanemab
Mechanism: Target amyloid-ß plaques
Initial assessment: Confirm amyloid beta pathology, ApoE ε4 status, prior to initiation
Administration: Monthly infusion for aducanumab (initial 1 mg/kg, increasing to 10 mg/KG over 24 weeks), and IV 10mg/kg every 2 weeks for Lecanemab

Aducanumab

Use: Mild cognitive impairment or mild dementia; evidence of amyloid buildup, as it's not indicated in earlier or later stages.
Co-administration: Can be co-administered with other AD drugs like cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and psychotropic agents.

Aducanumab - Safety Monitoring

ARIA (Amyloid-related imaging abnormalities): Edema and microhemorrhage
Monitoring: Clinical symptoms like headache, confusion, vision disturbances. Serial cognitive testing with family reporting. MRI scans prior to initiating therapy and at 5th, 7th and 12th doses.

Dosing protocol of Aducanumab

(Flow chart showing Aducanumab dosing protocol showing initial dose, interval, treatment duration and criteria for stopping treatment)

Management of behavioral and psychological symptoms of dementia (BPSD)

Categories and Medications: Depression: Escitalopram, Mirtazapine; Sleep-Wake Cycle Modulators: Melatonin; Atypical Antipsychotics: Aripiprazole, Risperidone, Olanzapine, Quetiapine; Psychotic Episodes: Pimavanserin; Carbamazepine, Levetiracetam; Lithium; Mood Stabilizer: Methylphenidate; Stimulant: Brexpiprazole; Agitation: Brexpiprazole

AD - Alternative Treatments

Studies showing use: Selegiline, Amyloid Therapy, Estrogen Therapy, Anti-inflammatory agents (NSAIDs), Cholesterol-lowering medications
Herbal/dietary supplements: Ginkgo biloba, Coenzyme Q, Omega-3 fatty acids, Vitamin E
Important Note: No scientific evidence of effectiveness

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Description

This quiz explores key aspects of Alzheimer's disease, including cognitive assessment tools and treatment recommendations. It also highlights important factors that can impact patient care, such as social and comorbid conditions. Test your knowledge on effective management strategies for patients like Mrs. Fatima.